Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $2.00. The company’s shares opened today at $0.40.

Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Revance Therapeutics, and Sarepta Therapeutics. According to TipRanks, Ear has an average return of 1.9% and a 39.27% success rate on recommended stocks.

Currently, the analyst consensus on IN8bio is a Strong Buy with an average price target of $3.73, an 835.78% upside from current levels. In a report released today, JonesTrading also upgraded the stock to a Buy with a $1.20 price target.

INAB market cap is currently $18.85M and has a P/E ratio of -0.36.